Physician profile
Robert Mosteller
NPI 1871678011
$9,301.04
in general payments reported to CMS, 2019-2025
22 companies · $3,496 in 2025
The $3,496 reported for 2025 was more than what 89% of Cardiovascular Disease providers received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,922 · 2020: $32.57 · 2021: $412 · 2022: $578 · 2023: $1,453 · 2024: $408 · 2025: $3,496.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,718 · Travel and Lodging: $1,396 · Consulting Fee: $243.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,718.49 |
| Travel and Lodging | $1,396.24 |
| Consulting Fee | $242.50 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Medtronic, INC. | $3,307.71 | 2022-2025 | Micra, Aurora Ev-Icd Mri Surescan, Mycarelink |
| Medtronic Vascular, INC. | $2,099.79 | 2019 | |
| Abbott Laboratories | $900.19 | 2019-2025 | Aveir, Ensite, Jot Dx |
| Medical Device Business Services, INC. | $672.71 | 2019 | |
| Atricure, INC. | $511.40 | 2021-2025 | Synergy Ablation System |
| Boston Scientific Corporation | $492.03 | 2019-2025 | Watchman Access System, Vigilant X4 Crt-D, Accolade Sr |
| Biosense Webster, INC. | $410.07 | 2024-2025 | Carto 3 |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $191.36 | 2022-2024 | Lifevest |
| E.R. Squibb & Sons, L.L.C. | $158.30 | 2021-2025 | Camzyos |
| Janssen Pharmaceuticals, INC | $130.24 | 2019-2021 | |
| Impulse Dynamics (USA) INC. | $122.37 | 2023 | Optimizer |
| Merck Sharp & Dohme LLC | $49.98 | 2023-2025 | Winrevair, Verquvo |
| Bridgebio Pharma, INC. | $49.16 | 2025 | Attruby |
| Novartis Pharmaceuticals Corporation | $39.45 | 2024-2025 | |
| Actelion Pharmaceuticals US, INC. | $35.23 | 2024 | Opsumit |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $32.60 | 2023-2024 | Rybelsus, Ozempic |
| Scpharmaceuticals INC. | $18.47 | 2025 | |
| Pfizer INC. | $17.77 | 2024 | |
| Esperion Therapeutics, INC. | $17.29 | 2025 | Nexletol |
| Astrazeneca Pharmaceuticals Lp | $15.54 | 2024 | Farxiga |
| Alnylam Pharmaceuticals INC. | $15.00 | 2025 | Onpattro |
| Terumo Medical Corporation | $14.38 | 2023 | Metacross Otw, Glidewire, Heartrail |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Robert Mosteller listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.